postpartum%20hemorrhage
POSTPARTUM HEMORRHAGE
Postpartum hemorrhage is defined as blood loss of ≥500 mL for vaginal delivery or 1000 mL for abdominal (Caesarean) delivery after completion of the 3rd stage of labor.
Another proposed definition is a 10% fall in hematocrit value.
Since the clinical estimation of the amount of blood loss is typically inaccurate, the diagnosis of postpartum hemorrhage remains a subjective clinical assessment of the amount of blood loss that jeopardizes a woman's hemodynamic stability.
Postpartum hemorrhage may produce hemodynamic instability during the 1st 24 hours after delivery.

Monitoring

Monitor Response to Treatment

  • Sensorium
  • Vital signs
  • Urine output
    • A urine output of >30 mL/hr is an objective sign of adequate renal perfusion
  • Complete blood count (CBC), coagulation
    • Blood sample is drawn to assess hematologic and metabolic profile, electrolytes, coagulation, acid-base oxygenation status
  • Evaluate tissue perfusion
    • Measure serum lactate and base deficit 
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 07 Aug 2018
A home-based, self-applied wearable electrocardiogram (ECG) patch facilitates diagnosis of atrial fibrillation (AF) among high-risk individuals, according to the mSToPS* trial.
Roshini Claire Anthony, 2 days ago

A genotype-guided approach to warfarin dosing may result in fewer dose adjustments in Asian patients, according to a study from Singapore.

4 days ago

Fungal microbiome, also called the mycobiome, appears to be highly variable in patients with well-characterized fungal diseases, a recent study has shown. Moreover, severe asthmatics have the highest fungal loads, along with those receiving steroid and antifungal therapy.

Audrey Abella, 07 Aug 2018
The use of the investigational first-in-class attachment inhibitor fostemsavir led to improved baseline viral and CD4+ T-cell counts in patients with HIV-1 infection who had limited treatment options and were failing their current antiretroviral regimen, according to the subgroup analysis results of the BRIGHTE* study presented at AIDS 2018.